Study on cisplatin combination with pemetrexed disodium in the therapy for malignant pleural mesothelioma

VernacularTitle:培美曲塞联合顺铂治疗恶性间皮瘤的疗效分析
Author: Shilong WEN ; Jiandong CUI
Publication Type:Journal Article
Keywords: Malignant pleural mesothelioma; Pemetrexed; Cisplatin; Drug therapy,combination; Progression-free survival; Survival rate
From: Cancer Research and Clinic 2011;23(11):736-738
CountryChina
Language:Chinese
Abstract: Objective To explore the clinical efficacy of ALIMTA (pemetrexed disodium) plus cisplatin.Methods Patients with malignant mesothelioma were allocated to two treatment groups envelope:pemetrexed plus cisplatin (PEM-group) or cisplatin alone (DDP-group).Results A total of 64 patients were randomly assigned and evaluated.The number of patients in PEM- and DDP-group had a significant pathologic complete response were (56.25 ％ vs 21.88 ％,x2 =7.943,P ＜0.05).Progression-free survival was significantly higher in PEM-group (P ＜0.05),and 2-year survival rate was lower in DDP-group (P ＜0.05).Conclusion Pemetrexed elicit significant tumor response and delays disease progression compared with DDP alone in patients with advanced MPM.Improvement in OS is seen in this study.